Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors inside the central anxious system, conolidine modulates alternate molecular targets. A Science Advancements research located that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7,